J Coen Netelenbos
Overview
Explore the profile of J Coen Netelenbos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verheij V, Diecidue R, Botman E, Harrington J, Haga N, Hidalgo-Bravo A, et al.
Expert Opin Pharmacother
. 2025 Jan;
26(3):291-299.
PMID: 39834193
Introduction: Palovarotene is a retinoic acid receptor gamma agonist that was studied in phase-2 and phase-3 clinical trials for the inhibition of new heterotopic ossification (HO) in fibrodysplasia ossificans progressiva...
2.
Botman E, Treurniet S, Lubbers W, Schwarte L, Schober P, Sabelis L, et al.
Front Endocrinol (Lausanne)
. 2020 Sep;
11:570.
PMID: 32973683
Fibrodysplasia ossificans progressiva (FOP) is a rare disease in which heterotopic ossification (HO) is formed in muscles, tendons and ligaments. Traumatic events, including surgery, are discouraged as this is known...
3.
Eekhoff E, Micha D, Forouzanfar T, de Vries T, Netelenbos J, Klein-Nulend J, et al.
Front Endocrinol (Lausanne)
. 2020 Aug;
11:481.
PMID: 32849274
In the field of rare bone diseases in particular, a broad care team of specialists embedded in multidisciplinary clinical and research environment is essential to generate new therapeutic solutions and...
4.
Botman E, Teunissen B, Raijmakers P, de Graaf P, Yaqub M, Treurniet S, et al.
JBMR Plus
. 2020 Jun;
4(6):e10363.
PMID: 32537549
Using [F] Sodium Fuoride (NaF) Positron Emission Tomography (PET) it is not only possible to identify the ossifying potency of a flare-up, but also to identify an asymptomatic chronic stage...
5.
Merlijn T, Swart K, van Schoor N, Heymans M, van der Zwaard B, van der Heijden A, et al.
J Bone Miner Res
. 2019 Jun;
34(11):1993-2000.
PMID: 31220365
Population screening for fracture risk may reduce the fracture incidence. In this randomized pragmatic trial, the SALT Osteoporosis Study (SOS), we studied whether screening for fracture risk and subsequent treatment...
6.
Eekhoff E, Netelenbos J, de Graaf P, Hoebink M, Bravenboer N, Micha D, et al.
JBMR Plus
. 2018 Oct;
2(1):55-58.
PMID: 30283890
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder leading to progressive heterotopic ossifications (HO) of muscles, tendons, and ligaments, which can be induced by trauma or by surgery. Despite...
7.
Swart K, Merlijn T, Netelenbos J, Elders P
Lancet
. 2018 Aug;
392(10147):552.
PMID: 30152385
No abstract available.
8.
Eekhoff E, Botman E, Netelenbos J, de Graaf P, Bravenboer N, Micha D, et al.
Bone
. 2017 Aug;
109:143-146.
PMID: 28826841
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease with a progressive course characterized by episodically local flare-ups, which often but not always leads to heterotopic bone formation (HO). Recently,...
9.
Compston J, Wyman A, FitzGerald G, Adachi J, Chapurlat R, Cooper C, et al.
J Bone Miner Res
. 2016 Feb;
31(7):1466-72.
PMID: 26861139
Increased fracture risk has been associated with weight loss in postmenopausal women, but the time course over which this occurs has not been established. The aim of this study was...
10.
Bravenboer N, Micha D, Triffit J, Bullock A, Ravazollo R, Bocciardi R, et al.
Eur J Hum Genet
. 2015 Jan;
23(10).
PMID: 25604857
No abstract available.